Get access

Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection

Authors

  • JMV Pons,

    1. Agència d’Avaluació de Tecnologia i Recerca Mèdiques (Catalan Agency for Health Technology Assessment and Research), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
    2. CIBER Epidemiología y Salud Pública, Spain
    Search for more papers by this author
  • C Tebé,

    1. Agència d’Avaluació de Tecnologia i Recerca Mèdiques (Catalan Agency for Health Technology Assessment and Research), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
    2. CIBER Epidemiología y Salud Pública, Spain
    Search for more papers by this author
  • N Paladio,

    1. Agència d’Avaluació de Tecnologia i Recerca Mèdiques (Catalan Agency for Health Technology Assessment and Research), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
    2. CIBER Epidemiología y Salud Pública, Spain
    Search for more papers by this author
  • A Garcia-Altes,

    1. CIBER Epidemiología y Salud Pública, Spain
    2. Fundación Instituto de Investigación en Servicios de Salud, Valencia, Spain
    3. Agència de Salut Pública de Barcelona (Barcelona Public Health Agency), Barcelona, Spain
    Search for more papers by this author
  • I Danés,

    1. Fundació Institut Català de Farmacologia (Catalan Institute of Pharmacology), Servei Farmacologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain
    Search for more papers by this author
  • A Valls-i-Soler

    1. Professor of Paediatrics, University of the Basque Country, Head Neonatal Intensive Care Unit, Hospital de Cruces (Barakaldo-Bilbao), Spain
    Search for more papers by this author

Joan MV Pons, Department of Health, Generalitat de Catalunya, Travessera de les Corts, 131-159 Pavelló Ave Maria, 08028 Barcelona, Spain. Tel: +34 93 556 64 74 | Fax: +34 93 227 29 92 |
Email: joan.ponsr@gencat.cat

Abstract

Aim:  To review respiratory syncytial virus (RSV), passive immunoprophylaxis (PI) trials and meta-analysis (MA).

Methods:  A literature review.

Results:  Two MA of PI were found. Overall 3927 patients were randomized. PI reduces RSV hospitalization in patients with bronchopulmonary dysplasia (RR 0.58; 95% CI 0.41, 0.82) and with acyanotic congenital heart disease (RR 0.29; 95% CI 0.14, 0.62). In patients with cyanotic heart disease or premature infants without bronchopulmonary dysplasia, results are inconclusive. Passive immunoprophylaxis has a null effect in mechanical ventilation and death.

Conclusion:  Passive immunoprophylaxis reduces RSV hospitalization in a subset of patients. However, it has no effect in harder endpoints of RSV disease severity.

Get access to the full text of this article

Ancillary